新型疫苗研发方法。
Novel approaches for vaccine development.
机构信息
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
Moderna, Inc., Cambridge, MA, USA.
出版信息
Cell. 2021 Mar 18;184(6):1589-1603. doi: 10.1016/j.cell.2021.02.030.
Abstract
Vaccines are critical tools for maintaining global health. Traditional vaccine technologies have been used across a wide range of bacterial and viral pathogens, yet there are a number of examples where they have not been successful, such as for persistent infections, rapidly evolving pathogens with high sequence variability, complex viral antigens, and emerging pathogens. Novel technologies such as nucleic acid and viral vector vaccines offer the potential to revolutionize vaccine development as they are well-suited to address existing technology limitations. In this review, we discuss the current state of RNA vaccines, recombinant adenovirus vector-based vaccines, and advances from biomaterials and engineering that address these important public health challenges.
摘要
疫苗是维护全球健康的重要工具。传统的疫苗技术已经广泛应用于各种细菌和病毒病原体，但也有一些例子表明它们并不成功，例如持续性感染、具有高度序列变异性的快速进化病原体、复杂的病毒抗原和新兴病原体。新型技术，如核酸和病毒载体疫苗，具有改变疫苗开发的潜力，因为它们非常适合解决现有技术的局限性。在这篇综述中，我们讨论了 RNA 疫苗、重组腺病毒载体疫苗的现状，以及生物材料和工程学方面的进展，这些进展都有助于应对这些重要的公共卫生挑战。
相似文献
1
Novel approaches for vaccine development.
Cell. 2021 Mar 18;184(6):1589-1603. doi: 10.1016/j.cell.2021.02.030.
2
Messenger RNA vaccines against SARS-CoV-2.
Cell. 2021 Mar 18;184(6):1401. doi: 10.1016/j.cell.2020.12.039. Epub 2021 Jan 13.
3
COVID-19 mRNA vaccines.
J Genet Genomics. 2021 Feb 20;48(2):107-114. doi: 10.1016/j.jgg.2021.02.006. Epub 2021 Mar 15.
4
Durability of Booster mRNA Vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 Subvariants.
N Engl J Med. 2022 Oct 6;387(14):1329-1331. doi: 10.1056/NEJMc2210546. Epub 2022 Sep 7.
5
Long-term stability and immunogenicity of lipid nanoparticle COVID-19 mRNA vaccine is affected by particle size.
Hum Vaccin Immunother. 2024 Dec 31;20(1):2342592. doi: 10.1080/21645515.2024.2342592. Epub 2024 May 7.
6
Engineering mRNA vaccine with broad-spectrum protection against SARS-cov-2 variants.
Biochem Biophys Res Commun. 2025 Feb;746:151224. doi: 10.1016/j.bbrc.2024.151224. Epub 2024 Dec 25.
7
The Nanoparticle-Enabled Success of COVID-19 mRNA Vaccines and the Promise of Microneedle Platforms for Pandemic Vaccine Response.
DNA Cell Biol. 2022 Jan;41(1):25-29. doi: 10.1089/dna.2021.0538. Epub 2021 Dec 24.
8
Design and development of mRNA and self-amplifying mRNA vaccine nanoformulations.
Nanomedicine (Lond). 2024;19(30):2699-2725. doi: 10.1080/17435889.2024.2419815. Epub 2024 Nov 13.
9
Safety of mRNA-Based Vaccines for SARS CoV-2.
Chem Res Toxicol. 2021 Aug 16;34(8):1823-1825. doi: 10.1021/acs.chemrestox.1c00129. Epub 2021 May 19.
10
Introduction to RNA Vaccines Post COVID-19.
Methods Mol Biol. 2024;2786:1-22. doi: 10.1007/978-1-0716-3770-8_1.
引用本文的文献
1
Computational identification of membrane proteins for vaccine design against drug-resistant Moraxella catarrhalis.
Mol Genet Genomics. 2025 Sep 6;300(1):92. doi: 10.1007/s00438-025-02288-w.
2
Codon Usage Evolution in Viruses: Implications for Survival and Pathogenicity.
J Mol Evol. 2025 Sep 4. doi: 10.1007/s00239-025-10263-7.
3
Method validation and assessment of the biodistribution and shedding for adenovirus vector-based vaccine using qPCR and dPCR.
Mol Ther Methods Clin Dev. 2025 Aug 5;33(3):101549. doi: 10.1016/j.omtm.2025.101549. eCollection 2025 Sep 11.
4
Optimizing Immunization Strategies for Individuals Living with HIV: A Review of Essential Vaccines, Vaccine Coverage, and Adherence Factors.
Vaccines (Basel). 2025 Jul 28;13(8):798. doi: 10.3390/vaccines13080798.
5
Nanotechnology-based mRNA vaccines.
Nat Rev Methods Primers. 2023;3(1). doi: 10.1038/s43586-023-00246-7. Epub 2023 Aug 17.
6
mRNA Vaccine Development in the Fight Against Zoonotic Viral Diseases.
Viruses. 2025 Jul 8;17(7):960. doi: 10.3390/v17070960.
7
Latest advances and prospects in the pathogenesis, animal models, and vaccine research of severe fever with thrombocytopenia syndrome virus.
Front Immunol. 2025 Jun 26;16:1624290. doi: 10.3389/fimmu.2025.1624290. eCollection 2025.
8
TransMA: an explainable multi-modal deep learning model for predicting properties of ionizable lipid nanoparticles in mRNA delivery.
Brief Bioinform. 2025 May 1;26(3). doi: 10.1093/bib/bbaf307.
9
Neoantigen-Based Immunotherapy in Lung Cancer: Advances, Challenges and Prospects.
Cancers (Basel). 2025 Jun 12;17(12):1953. doi: 10.3390/cancers17121953.
10
Vaccines for preventing infections in adults with haematological malignancies.
Cochrane Database Syst Rev. 2025 May 21;5(5):CD015530. doi: 10.1002/14651858.CD015530.pub2.
本文引用的文献
1
mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents.
NPJ Vaccines. 2021 Apr 16;6(1):57. doi: 10.1038/s41541-021-00311-w.
2
Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine.
N Engl J Med. 2021 May 13;384(19):1824-1835. doi: 10.1056/NEJMoa2034201. Epub 2021 Jan 13.
3
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.
4
Integrating Biomaterials and Immunology to Improve Vaccines Against Infectious Diseases.
ACS Biomater Sci Eng. 2020 Feb 10;6(2):759-778. doi: 10.1021/acsbiomaterials.9b01255. Epub 2020 Jan 12.
5
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. Epub 2020 Dec 8.
6
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.
7
Association of Use of a Meningococcus Group B Vaccine With Group B Invasive Meningococcal Disease Among Children in Portugal.
JAMA. 2020 Dec 1;324(21):2187-2194. doi: 10.1001/jama.2020.20449.
8
Implementation of accelerated research: strategies for implementation as applied in a phase 1 Ad26.ZEBOV, MVA-BN-Filo two-dose Ebola vaccine clinical trial in Uganda.
Glob Health Action. 2020 Dec 31;13(1):1829829. doi: 10.1080/16549716.2020.1829829.
9
COVID-19 Vaccine Frontrunners and Their Nanotechnology Design.
ACS Nano. 2020 Oct 27;14(10):12522-12537. doi: 10.1021/acsnano.0c07197. Epub 2020 Oct 9.
10
Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study.
Lancet HIV. 2020 Oct;7(10):e688-e698. doi: 10.1016/S2352-3018(20)30229-0.
Zotero 插件